228 related articles for article (PubMed ID: 8929495)
1. Quantification and pharmacokinetics of blood-brain barrier disruption in humans.
Zünkeler B; Carson RE; Olson J; Blasberg RG; DeVroom H; Lutz RJ; Saris SC; Wright DC; Kammerer W; Patronas NJ; Dedrick RL; Herscovitch P; Oldfield EH
J Neurosurg; 1996 Dec; 85(6):1056-65. PubMed ID: 8929495
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study.
Shapiro WR; Voorhies RM; Hiesiger EM; Sher PB; Basler GA; Lipschutz LE
Cancer Res; 1988 Feb; 48(3):694-701. PubMed ID: 3335031
[TBL] [Abstract][Full Text] [Related]
3. Hyperosmolar blood-brain barrier disruption in baboons: an in vivo study using positron emission tomography and rubidium-82.
Zünkeler B; Carson RE; Olson J; Blasberg RG; Girton M; Bacher J; Herscovitch P; Oldfield EH
J Neurosurg; 1996 Mar; 84(3):494-502. PubMed ID: 8609564
[TBL] [Abstract][Full Text] [Related]
4. [ACNU delivery to malignant glioma tissue by osmotic blood brain barrier modification with intracarotid infusion of hyperosmoral mannitol].
Miyagami M; Kagawa Y; Tsubokawa T
No Shinkei Geka; 1985 Sep; 13(9):955-63. PubMed ID: 2999632
[TBL] [Abstract][Full Text] [Related]
5. Repeated, short-term ischemia augments bradykinin-mediated opening of the blood-tumor barrier in rats with RG2 glioma.
Liu Y; Hashizume K; Samoto K; Sugita M; Ningaraj N; Asotra K; Black KL
Neurol Res; 2001 Sep; 23(6):631-40. PubMed ID: 11547933
[TBL] [Abstract][Full Text] [Related]
6. Visual evoked responses as a monitor of intracranial pressure during hyperosmolar blood-brain barrier disruption.
Gumerlock MK; York D; Durkis D
Acta Neurochir Suppl (Wien); 1994; 60():132-5. PubMed ID: 7976525
[TBL] [Abstract][Full Text] [Related]
7. Evidence that Cereport's ability to increase permeability of rat gliomas is dependent upon extent of tumor growth: implications for treating newly emerging tumor colonies.
Bartus RT; Snodgrass P; Dean RL; Kordower JH; Emerich DF
Exp Neurol; 2000 Jan; 161(1):234-44. PubMed ID: 10683290
[TBL] [Abstract][Full Text] [Related]
8. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.
Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM
J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648
[TBL] [Abstract][Full Text] [Related]
9. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
[TBL] [Abstract][Full Text] [Related]
10. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
12. Selective blood-tumor barrier disruption by leukotrienes.
Chio CC; Baba T; Black KL
J Neurosurg; 1992 Sep; 77(3):407-10. PubMed ID: 1506887
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiological aspects of malignant brain tumors studied with positron emission tomography.
Jarden JO
Acta Neurol Scand Suppl; 1994; 156():1-35. PubMed ID: 7941966
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption.
Neuwelt EA; Diehl JT; Vu LH; Hill SA; Michael AJ; Frenkel EP
Ann Intern Med; 1981 Apr; 94(4 pt 1):449-54. PubMed ID: 6782926
[TBL] [Abstract][Full Text] [Related]
15. Effect of hyperosmotic blood-brain barrier disruption on transcapillary transport in canine brain tumors.
Groothuis DR; Warkne PC; Molnar P; Lapin GD; Mikhael MA
J Neurosurg; 1990 Mar; 72(3):441-9. PubMed ID: 2106016
[TBL] [Abstract][Full Text] [Related]
16. Enhanced therapeutic agent delivery through magnetic resonance imaging-monitored focused ultrasound blood-brain barrier disruption for brain tumor treatment: an overview of the current preclinical status.
Liu HL; Yang HW; Hua MY; Wei KC
Neurosurg Focus; 2012 Jan; 32(1):E4. PubMed ID: 22208897
[TBL] [Abstract][Full Text] [Related]
17. Opening blood-brain-barrier by intracarotid infusion of papaverine in treatment of malignant cerebral glioma.
Xue H; Wang H; Kong L; Zhou H
Chin Med J (Engl); 1998 Aug; 111(8):751-3. PubMed ID: 11245034
[TBL] [Abstract][Full Text] [Related]
18. [The effect on the tumor vessel permeability by hyperosmotic blood brain barrier disruption].
Miyagami M; Tazoe M; Kagawa Y; Tsubokawa T
No To Shinkei; 1988 Sep; 40(9):875-82. PubMed ID: 3142506
[TBL] [Abstract][Full Text] [Related]
19. Mannitol opening of the blood-brain barrier: regional variation in the permeability of sucrose, but not 86Rb+ or albumin.
Brown RC; Egleton RD; Davis TP
Brain Res; 2004 Jul; 1014(1-2):221-7. PubMed ID: 15213006
[TBL] [Abstract][Full Text] [Related]
20. Quantitative autoradiographic measurements of blood-brain barrier permeability in the rat glioma model.
Yamada K; Ushio Y; Hayakawa T; Kato A; Yamada N; Mogami H
J Neurosurg; 1982 Sep; 57(3):394-8. PubMed ID: 7097336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
